Save the Date

Guests are welcome. Seating is Limited. 
For event inquiries or RSVPs, please email by February 5th.


Meet The Presenters:

 Eli Casdin – Founder and Chief Investment Officer, Casdin Capital Life Science Investments

In the fall of 2011, Eli founded his fast-growing growth equity fund in the equally fast-growing sector of Life Sciences handily outperforming a sector-wide upswing. Casdin Capital’s strategy and success lies in its deep fundamental research and participation in all aspects of the life science revolution; from diagnostics to information systems to molecular medicines into industrial biotech applications. As Casdin often points out, genomics is a data-driven paradigm shift that is fundamentally reshaping the entire healthcare and life science industry, much as Silicon Valley and the semi-conductor reshaped our social and commercial lives, creating a diversity of investment opportunities along the way.  Over the last 16 years, including writing a black book, The Dawn of Molecular Medicine, Eli Casdin has been both investor in and partner to many of the key thinkers and companies bringing these disruptive technologies to market. Casdin’s combination of long-term vision and strong industry relationships keep focused on the big picture yet remain nimble, while maintaining a consistent approach: Take aim at big markets; Invest in great ideas and great teams; Stay focused; Avoid hubris. Prior to founding Casdin Capital, Eli was a Vice President and Analyst at Alliance Bernstein and a member of its “thematic” based investment group, responsible for researching and investing in the implications of new technologies for the life science and healthcare sectors. Eli’s early experience includes time at Bear Stearns and at Cooper Hill Partners, one of the earliest biotechnology-focused investment firms. Eli earned his B.S. from Columbia University and his MBA from Columbia Business School and serves on the Columbia University School of GS Board of Directors. He also serves on the Board of Directors for Exact Sciences, Prominex Dx, Genomatica, and Tenaya Therapeutics as well as participates as a board observer of several early stage therapeutic companies.


Michael G. Dow, CFA, CPA – Chief Investment Officer, Beacon Pointe

Michael is the Chief Investment Officer of Beacon Pointe Advisors and the Chairman of the Beacon Pointe Investment Committee. Prior to joining Beacon Pointe, Michael served as Managing Director and Head of US Core Plus Bonds, Head of Sovereign Credit Research, and Head of Emerging Market Corporate Debt at UBS Global Asset Management, where he was responsible for portfolio management, research, trading and strategy across the UBS global platform for these products. Prior to joining UBS, Michael was enrolled at the University of Chicago and studied in several post-graduate programs including Economics and in the School of Public Policy and had begun the core coursework in the PhD Finance program at the Chicago Booth School before returning to the capital markets in early 2008. He remains affiliated with the University of Chicago and has taught the undergraduate Intermediate Accounting course at Lake Forest College as an adjunct professor, and as a guest lecturer taught the fixed income and interest rate course sections of undergraduate finance and graduate quantitative finance programs at the University of Illinois, Northwestern University and Notre Dame University. Prior to academia Michael was an Investment Grade Corporate Bond Portfolio Manager at PIMCO and was the PIMCO Funds National Sales Manager, as well as a senior member of the Consultant Relations Group.  He started his career at Salomon Brothers as a fixed income salesman in the Private Investment Department. He received a BS in Accountancy from the University of Illinois Urbana-Champaign, where he played intercollegiate water polo, and his MBA in Finance from the University of Chicago.  Michael is a Chartered Financial Analyst, received his certificate to practice as a CPA (inactive) and is a member of the CFA Society of Chicago.


Derek Newcomer, CFA, CAIA – Director of Investment Research, Beacon Pointe

Derek leads investment manager research and due-diligence in the area of alternative investments, in addition to being a member of Beacon Pointe’s Investment Committee. Prior to Beacon Pointe, Derek held the role of Vice President at CRESO Capital Partners, Newport Beach, California, an investment banking firm focused on mezzanine investments, capital raising for preferred and common equity, and merger & acquisitions for privately held companies with revenues of $10MM to $250MM. His primary duties included client development as well preliminary financial and market due diligence of investment opportunities. He is a graduate of University of California at Santa Cruz with a major in Economics/Business Management. Derek has served as the Chair of the Investment Committee at the Goodwill of Orange County. He is a CFA Charterholder and a member of the CFA Society of Orange County and holds the designation of Chartered Alternative Investment Analyst (CAIA).

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.